ATE297925T1 - 3-substituierte oxindol beta 3 agonisten - Google Patents

3-substituierte oxindol beta 3 agonisten

Info

Publication number
ATE297925T1
ATE297925T1 AT02784193T AT02784193T ATE297925T1 AT E297925 T1 ATE297925 T1 AT E297925T1 AT 02784193 T AT02784193 T AT 02784193T AT 02784193 T AT02784193 T AT 02784193T AT E297925 T1 ATE297925 T1 AT E297925T1
Authority
AT
Austria
Prior art keywords
agonists
beta
oxindol
substituted
substituted oxindol
Prior art date
Application number
AT02784193T
Other languages
German (de)
English (en)
Inventor
Jolie Anne Bastian
Gerd Ruehter
Daniel Jon Sall
Theo Schotten
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE297925T1 publication Critical patent/ATE297925T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02784193T 2001-11-20 2002-11-12 3-substituierte oxindol beta 3 agonisten ATE297925T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33403401P 2001-11-20 2001-11-20
PCT/US2002/033624 WO2003044016A1 (en) 2001-11-20 2002-11-12 3-SUBSTITUTED OXINDOLE β3 AGONISTS

Publications (1)

Publication Number Publication Date
ATE297925T1 true ATE297925T1 (de) 2005-07-15

Family

ID=23305290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02784193T ATE297925T1 (de) 2001-11-20 2002-11-12 3-substituierte oxindol beta 3 agonisten

Country Status (8)

Country Link
US (1) US7205407B2 (enExample)
EP (1) EP1448560B1 (enExample)
JP (1) JP2005514366A (enExample)
AT (1) ATE297925T1 (enExample)
AU (1) AU2002347982A1 (enExample)
DE (1) DE60204718T2 (enExample)
ES (1) ES2242890T3 (enExample)
WO (1) WO2003044016A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60215028T2 (de) * 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
DE60225174T2 (de) * 2001-11-20 2009-02-12 Eli Lilly And Co., Indianapolis Beta-3 adrenergische agonisten
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
BRPI0510260A (pt) 2004-04-27 2007-10-23 Wyeth Corp método para purificar um composto, e, kit farmacêutico
CA2589363A1 (en) * 2004-12-13 2006-06-22 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
KR20070072142A (ko) * 2005-12-30 2007-07-04 엘지.필립스 엘시디 주식회사 전계 발광 표시장치와 그 구동방법
EP2073806B1 (en) * 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2008046049A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
BRPI0719166A2 (pt) * 2006-10-12 2014-06-03 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol tricíclicos e seus usos como agentes terapêuticos
HRP20150882T1 (hr) * 2008-10-17 2015-09-25 Xenon Pharmaceuticals Inc. Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
WO2010045197A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
RU2596488C2 (ru) 2010-02-26 2016-09-10 Ксенон Фармасьютикалз Инк. Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
EP2794565B1 (en) 2011-12-21 2017-07-26 Novira Therapeutics Inc. Hepatitis b antiviral agents
CA2881057C (en) 2012-08-28 2020-10-27 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
TW202126620A (zh) 2013-05-17 2021-07-16 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Ｈｂｖ感染の治療のための併用療法
PL3102572T3 (pl) 2014-02-06 2019-04-30 Janssen Sciences Ireland Uc Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
EP3271019A1 (en) 2015-03-19 2018-01-24 Novira Therapeutics Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AR106192A1 (es) 2015-09-29 2017-12-20 Novira Therapeutics Inc Formas cristalinas de un agente antiviral contra la hepatitis b
WO2017181141A2 (en) 2016-04-15 2017-10-19 Novira Therapeutics, Inc. Combinations and methods comprising a capsid assembly inhibitor
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
SG11202007097QA (en) 2018-03-14 2020-08-28 Janssen Sciences Ireland Unlimited Co Capsid assembly modulator dosing regimen
AU2020223865A1 (en) 2019-02-22 2021-07-15 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
BR112021021454A2 (pt) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Derivados de amida úteis no tratamento da infecção por hbv ou doenças induzidas por hbv

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624395A5 (enExample) 1976-01-08 1981-07-31 Ciba Geigy Ag
CA1116598A (en) 1977-07-13 1982-01-19 William T. Comer 3-indolyl-tertiary butylaminopropanols
US4234595A (en) * 1977-07-13 1980-11-18 Mead Johnson & Company 3-Indolyl-tertiary butylaminopropanols
US4314943A (en) * 1977-07-13 1982-02-09 Mead Johnson & Company Heterocyclic substituted aryloxy 3-indolyl-tertiary butylaminopropanols
JPS6010021B2 (ja) * 1979-01-31 1985-03-14 田辺製薬株式会社 新規ベンジルアルコ−ル誘導体及びその製法
DE3423429A1 (de) 1984-06-26 1986-01-02 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
DE3426419A1 (de) * 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4728651A (en) 1985-10-24 1988-03-01 Hoechst-Roussel Pharmaceuticals Inc. Antihypertensive thieno-isoxazoles and -pyrazoles
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
NO303782B1 (no) 1994-03-23 1998-08-31 Sankyo Co Tiazolidin- og oksazolidinderivater og farmas°ytiske preparater inneholdende slike, samt deres anvendelse til fremstilling av medikamenter
US5705515A (en) 1994-04-26 1998-01-06 Merck & Co., Inc. Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
US6075040A (en) * 1996-09-05 2000-06-13 Eli Lilly And Company Selective β3 adrenergic agonists
JP2000511903A (ja) 1996-06-07 2000-09-12 メルク エンド カンパニー インコーポレーテッド 糖尿病および肥満の治療のための選択性β▲下３▼作動薬としてのオキサジアゾール・ベンゼンスルホンアミド
EP0827746B1 (en) 1996-09-05 2002-04-03 Eli Lilly And Company Carbazole analogues as selective beta3 adrenergic agonists
IL131130A0 (en) 1997-01-28 2001-01-28 Merck & Co Inc Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity
US6011048A (en) * 1997-01-28 2000-01-04 Merck & Co., Inc. Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity
AUPP796798A0 (en) 1998-12-30 1999-01-28 Fujisawa Pharmaceutical Co., Ltd. New compound
JP2003055344A (ja) 1999-01-29 2003-02-26 Dainippon Pharmaceut Co Ltd ３，７−ジ置換インドール誘導体及びそれを含有する医薬組成物
WO2001007026A2 (en) * 1999-07-22 2001-02-01 Eli Lilly And Company Improved method of treating type ii diabetes and obesity
WO2001035947A2 (en) 1999-11-15 2001-05-25 Eli Lilly And Company Treating wasting syndromes with aryloxy propanolamines
WO2001036412A1 (en) 1999-11-15 2001-05-25 Eli Lilly And Company Process for the preparation of aryloxy propanolamines
AU2001236471A1 (en) 2000-01-18 2001-07-31 Neurogen Corporation Imidazopyridines and related azacyclic derivatives as selective modulators of bradykinin b2 receptors
HUP0301329A2 (hu) 2000-07-13 2003-08-28 Eli Lilly And Co. Béta3 Adrenergiás agonisták, valamint ezen vegyületeket tartalmazó gyógyászati készítmények és eljárás e vegyületek előállítására
DE60120748T2 (de) 2000-11-10 2007-05-16 Eli Lilly And Co., Indianapolis 3-substituierte oxindolderivate als beta-3-agonisten
US6911463B2 (en) * 2001-08-14 2005-06-28 Eli Lilly And Company 3-substituted oxindole β-3 agonists
DE60215028T2 (de) * 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
DE60225174T2 (de) * 2001-11-20 2009-02-12 Eli Lilly And Co., Indianapolis Beta-3 adrenergische agonisten

Also Published As

Publication number Publication date
US7205407B2 (en) 2007-04-17
JP2005514366A (ja) 2005-05-19
WO2003044016A1 (en) 2003-05-30
AU2002347982A1 (en) 2003-06-10
US20050020617A1 (en) 2005-01-27
DE60204718D1 (de) 2005-07-21
EP1448560A1 (en) 2004-08-25
DE60204718T2 (de) 2006-05-18
ES2242890T3 (es) 2005-11-16
EP1448560B1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
DE60204718D1 (de) 3-substituierte oxindol beta 3 agonisten
ATE329901T1 (de) 3-substituierte oxindolderivate als beta-3- agonisten
DE60211199D1 (de) 3-substituierte oxindol-beta-3-agonisten
ATE390922T1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
DE60215028D1 (de) Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
BR0112582A (pt) Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
AR006545A1 (es) Compuestos sustitutos de las catecolaminas, utiles como antagonistas beta3, composiciones farmaceuticas que los contienen y compuestos intermediarios deaplicacion exclusiva en la preparacion de dichos compuestos
ATE396186T1 (de) Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
DE60319714D1 (de) Agonisten des cannabinoidrezeptors
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
KR970703172A (ko) 모노아민, 디아민, 티올-함유 금속 킬레이터(monoamine, diamide, thiol-containing metal chelating agents)
DOP2000000106A (es) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida
DE602004006869D1 (de) 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit
BR0008112A (pt) Agonistas de 5-ht 1f
DE60233111D1 (de) Glucocorticoid-rezeptoren-modulatoren
BR0213481A (pt) Sondas
ATE341538T1 (de) Benzimidazolonderivate mit affinität zu serotonin-und dopaminrezeptoren
DK0888341T3 (da) Hidtil ukendte svovlderivater indeholdende en amidbinding, fremgangsmåde for fremstilling heraf, anvendelse heraf som lægemidler og farmaceutiske præparater indeholdende disse
DE60014343D1 (de) N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten
EP1293567A4 (en) GPR8 LIGAND AND DAFUER ENCODING DNA (02.01.02)
EA200100918A1 (ru) Агонисты 5-ht1f рецептора
DE60227421D1 (de) Rmazeutische zusammensetzung und verwendung davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties